Parameter
| Biomarker | CLP | Full name | Cardiac Lipid Panel (sphingomyelin, triglycerides, phosphatidylcholine) | Molecular Type | Metabolites (lipids) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | SM: ~700-800 Da; TAG: ~800-900 Da; PC: ~700-800 Da | Core Functional Dimensions | Early diagnosis and subtype evaluation | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Myocardium, liver, adipose tissue | Test Sample / Technology Platform | Plasma (LC-MS/MS, NMR) | ||
| Pathobiological Mechanisms | Containing sphingomyelin (SM), triglycerides (TAG), phosphatidyl choline (PC), reflect myocardial lipid metabolic disturbance, early asymptomatic HFrEF anomalies | ||||
| Clinical Availability Status | The validation: - Mueller-Hennessen etc. The study shows that the CLP in the diagnosis of early HFrEF AUC = 0.85 (0.78) is better than that of the NT-proBNP; -correlation with LVEF<40%, r=-0.47 | ||||
| Notes and Dynamics | (1) CLP can identify "asymptomatic HFrEF" | ||||